当前位置: X-MOL 学术Mol. Biol. Rep. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
IGFBP3 gene promoter methylation analysis and its association with clinicopathological characteristics of colorectal carcinoma.
Molecular Biology Reports ( IF 2.8 ) Pub Date : 2020-09-14 , DOI: 10.1007/s11033-020-05747-2
Alok Kumar 1, 2 , Pradyumn Singh 2 , Anshuman Pandey 3 , Sunil Babu Gosipatala 1
Affiliation  

Promoter methylation mediated silencing of tumor suppressor genes plays an important role in the tumorigenesis of colorectal carcinoma (CRC). Tumor suppressor gene, Insulin-like Growth Factor Binding Protein-3 (IGFBP-3) expression is frequently downregulated in CRC due to promoter methylations. The aim of this study was to analyze the methylation status of IGFBP-3 gene promoter in stage II and III of CRC cases; find its association with clinicopathological characteristics of CRC patients and the methylation patterns as a prognostic biomarker. 58 histopathologically confirmed cases of CRC were included in the study. Methylation status of IGFBP-3 gene promoter was determined by using methylation specific PCR (MS-PCR) and bisulfite sequencing. Kaplan–Meier survival curve and univariate cox regression analysis were used for survival analysis; Chi-square test used for association analysis. IGFBP3 promoter methylation was found in 37 (63.8%) out of 58 CRC cases. This promoter methylation status was significantly associated with lymph-node metastasis (P = 0.013) and the survival period. In stage II CRC cases, unmethylated gene promoter status showed better survival than the methylated. Mean overall survival (OS) of methylated and unmethylated group was 22.23 months, and 49.15 months respectively (P = 0.045), HR = 6.432, 95% CI 0.986–41.943. The IGFBP-3 promoter methylations found in 63.8% CRC cases in this study. The methylations was found to be associated with lymph-node metastasis and overall survival of the patients particularly in stage II CRC patients. However, promoter methylation was not associated with other clinocopathological characteristics such as age, gender, tumor location etc.



中文翻译:

IGFBP3基因启动子甲基化分析及其与大肠癌临床病理特征的关系。

启动子甲基化介导的肿瘤抑制基因沉默在结直肠癌(CRC)的肿瘤发生中起重要作用。由于启动子甲基化,肿瘤抑制基因胰岛素样生长因子结合蛋白3(IGFBP-3)的表达经常在CRC中下调。这项研究的目的是分析IGFBP-3基因启动子在CRC患者第二和第三阶段的甲基化状态。发现其与CRC患者的临床病理特征和甲基化模式相关,作为预后生物标志物。该研究包括58例经组织病理学证实的CRC病例。IGFBP-3的甲基化状态通过使用甲基化特异性PCR(MS-PCR)和亚硫酸氢盐测序确定基因启动子。Kaplan–Meier生存曲线和单变量Cox回归分析用于生存分析。卡方检验用于关联分析。在58例CRC病例中,有37例(63.8%)发现了IGFBP3启动子甲基化。该启动子甲基化状态与淋巴结转移(P = 0.013)和生存期显着相关。在II期CRC病例中,未甲基化的基因启动子状态显示出比甲基化更好的存活率。甲基化组和未甲基化组的平均总生存期(OS)分别为22.23个月和49.15个月(P = 0.045),HR = 6.432,95%CI 0.986–41.943。该IGFBP-3在这项研究中,在63.8%的CRC病例中发现了启动子甲基化。发现甲基化与患者的淋巴结转移和总体存活有关,特别是在II期CRC患者中。然而,启动子甲基化与其他年龄,性别,肿瘤位置等临床病理特征无关。

更新日期:2020-09-15
down
wechat
bug